Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Feb 4;7(4):FSO674.
doi: 10.2144/fsoa-2020-0210.

Urologic malignancies: advances in the analysis and interpretation of clinical findings

Felice Crocetto  1 , Carlo Buonerba  2 , Vincenzo Caputo  1 , Matteo Ferro  3   4 , Francesco Persico  5 , Francesco Trama  6 , Ester Iliano  6 , Sebastiano Rapisarda  7 , Maida Bada  8 , Gaetano Facchini  9 , Antonio Verde  10 , Sabino De Placido  10 , Biagio Barone  1
Affiliations
Editorial

Urologic malignancies: advances in the analysis and interpretation of clinical findings

Felice Crocetto et al. Future Sci OA. .
No abstract available

Keywords: biomarkers; immunotherapy; urologic malignancies.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure C Buonerba is a member of the Editorial Board of Future Science OA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J. Clin. 70, 7–30 (2020). - PubMed
    1. Rescigno P, Buonerba C, Bellmunt J et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 13, 1676–1686 (2012). - PubMed
    1. Pagliuca M, Buonerba C, Fizazi K et al. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs 79, 381–400 (2019). - PubMed
    1. Ferro M, Lucarelli G, Crocetto F et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit. Rev. Oncol. Hematol. 103198. (2020) (Epub ahead of print). - PubMed
    1. Buonerba C, Ferro M, Dolce P et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol . 151, 102992 (2020). - PubMed

Publication types